1. Home
  2. XAIR vs ADVB Comparison

XAIR vs ADVB Comparison

Compare XAIR & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$1.35

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

ADVB

Advanced Biomed Inc. Common Stock

HOLD

Current Price

$0.44

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
ADVB
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
9.7M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
XAIR
ADVB
Price
$1.35
$0.44
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
1.2M
344.4K
Earning Date
11-10-2025
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,802,000.00
N/A
Revenue This Year
$261.11
N/A
Revenue Next Year
$151.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.74
N/A
52 Week Low
$1.19
$0.34
52 Week High
$11.56
$4.10

Technical Indicators

Market Signals
Indicator
XAIR
ADVB
Relative Strength Index (RSI) 30.99 51.50
Support Level $1.19 $0.41
Resistance Level $1.38 $0.49
Average True Range (ATR) 0.11 0.04
MACD 0.01 0.00
Stochastic Oscillator 20.15 59.85

Price Performance

Historical Comparison
XAIR
ADVB

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About ADVB Advanced Biomed Inc. Common Stock

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

Share on Social Networks: